Subtype
Malignant Intestinal Neoplasm
CI-CAN-00001137Explore in graph →
1,666 active trials21 approved drugs383 evidence items
- NCIt
- C4572
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001137Explore in graph →
Clinical trials
7,773 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (772)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07365592 | Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC(Neo-CD) | recruiting | Phase 1 / Phase 2 | 138 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03017807 | Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY |
| 1 |
| May 12, 2026 |
| clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | recruiting | Phase 1 | 22 | University of California, IrvineOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | suspended | Phase 1 / Phase 2 | 53 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07417488 | GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas | recruiting | Phase 1 | 18 | Thomas Jefferson UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT05692024 | COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER(COMMENCER) | recruiting | Phase 1 / Phase 2 | 80 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07566897 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 96 | Philogen S.p.A.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04511039 | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | recruiting | Phase 1 | 45 | Roswell Park Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02837263 | PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | completed | Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07283367 | A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. | recruiting | Phase 1 / Phase 2 | 502 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07561060 | Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy(TNTIT) | recruiting | Phase 1 / Phase 2 | 50 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 124 | MacroGenicsINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04868773 | Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy | completed | Phase 1 | 15 | University of California, IrvineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT01787500 | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | completed | Phase 1 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06720987 | A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | recruiting | Phase 1 | 140 | Kumquat Biosciences Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT07542704 | A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies | not yet recruiting | Phase 1 | 48 | Kumquat Biosciences Inc.INDUSTRY | 0 | Apr 21, 2026 | clinicaltrials |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | terminated | Phase 1 | 21 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT07353645 | KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 49 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02151019 | Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer(TRI-LARC) | terminated | Phase 1 / Phase 2 | 94 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06848465 | LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis | recruiting | Phase 1 | 9 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03798626 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | completed | Phase 1 | 167 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 1, 2026 | clinicaltrials |
| NCT07504523 | Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer | recruiting | Phase 1 | 20 | Ying Yuan, MDOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07504263 | Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies | not yet recruiting | Phase 1 / Phase 2 | 66 | Recurv Pharma IncINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT04703101 | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | recruiting | Phase 1 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05039177 | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies(HERKULES-3) | completed | Phase 1 / Phase 2 | 101 | Erasca, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05427487 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | recruiting | Phase 1 | 70 | ImmVirx Pty LtdINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07491159 | Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study | active not recruiting | Phase 1 / Phase 2 | 106 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | terminated | Phase 1 | 4 | PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-01) | active not recruiting | Phase 1 / Phase 2 | 344 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation(ALAFOSS-01) | terminated | Phase 1 | 17 | AstraZenecaINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT06336902 | Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | recruiting | Phase 1 | 15 | University of Southern CaliforniaOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04808323 | MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer | recruiting | Phase 1 | 22 | Medical College of WisconsinOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05194995 | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | active not recruiting | Phase 1 / Phase 2 | 48 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03223779 | Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer | completed | Phase 1 / Phase 2 | 52 | Massachusetts General HospitalOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05382364 | Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) | active not recruiting | Phase 1 | 25 | PfizerINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT02213913 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | University of ChicagoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2026source: clinicaltrials